Not all demand is for new chemistry. Some of the sharpest signals in our radar come from molecules that have existed for decades — even a century — suddenly accelerating. The most striking is Rose Bengal, a rose-colored dye first made in the 1880s.
From the Knitify Pharma Demand Radar — our running read on where pharmaceutical demand is heading. We publish the observations; the method behind them stays in-house.
An old molecule, a new life
Rose Bengal spent most of its existence as a textile dye and a diagnostic stain — the kind of workaday chemical no one expected to headline a cancer program. Today it's accelerating in the patent record as a cancer therapy, an injectable agent (developed under the name PV-10) that triggers an immune response against tumors and has been carried into clinical trials for melanoma, including checkpoint-inhibitor combinations. [1] And it isn't alone: the radar is full of old generics — anesthetics, sedatives, first-generation antivirals — whose demand is climbing again.
Here's the demand hiding inside that story. To develop Rose Bengal as an oncology drug, its maker had to build a patented, commercial-scale process to produce it as a pharmaceutical-grade API — because a molecule that was perfectly fine as a dye is not automatically fit to inject into a patient. The demand isn't for a new molecule. It's for a new grade, a new process, and a new supply chain wrapped around an old one. The compound didn't change. What changed was the question being asked of it, and the standard it now has to meet.
Why one molecule does more than one thing
Repurposing works because drugs are rarely as specific as their labels suggest. A molecule shaped to fit one protein usually fits several others too — a property called polypharmacology. Biological targets are not unique locks; many share structural pockets, and a compound tuned for one can bind, weakly or strongly, to a whole family of them. That promiscuity is often treated as a nuisance in early drug design, but it is exactly what lets a compound built for one purpose turn out to act on a completely different disease's biology.
Seen this way, a drug is less a single-purpose tool than a chemical structure with a range of latent activities, only some of which were understood when it was first made. A nineteenth-century dye can trigger an anti-tumor immune response; a sedative can interfere with the biology of a blood cancer; a cardiovascular compound can relax smooth muscle somewhere no one was looking. The molecule was always capable of it. The science simply hadn't asked the right question yet — and when it finally does, demand for the old compound reappears, sometimes decades after everyone assumed its story was over.
Repurposing is the rule, not the exception
The history of medicine is full of molecules that found their real calling on the second or third try. Thalidomide is the most dramatic: a sedative withdrawn after a catastrophe with birth defects, it re-entered medicine much later as a treatment for multiple myeloma and complications of leprosy — the same molecule, a completely different use. Sildenafil was investigated for cardiovascular indications before its side-effect profile redirected it toward erectile dysfunction and, later, pulmonary hypertension. Even aspirin, one of the oldest drugs in the cabinet, migrated from a simple pain reliever to a cornerstone of cardiovascular prevention on the strength of an activity no one prescribed it for originally.
These are not curiosities. They are the visible tip of a systematic pattern: it is often cheaper, faster, and safer to find a new use for a known molecule than to invent one from scratch. Each of these examples represents demand that appeared without any new chemistry being discovered — the compound was already on the shelf, waiting for the indication to catch up. For a manufacturer, that is the point worth internalizing: the molecule that suddenly needs to be made in volume tomorrow may be one that has existed, quietly, for decades.
Dye-grade and drug-grade are not the same thing
The gap between "this molecule exists" and "this molecule can be injected" is where the real work lives. An industrial or reagent-grade chemical only has to be good enough for its job — a dye has to color reliably, a reagent has to react predictably. Trace impurities, residual solvents, and inconsistent batches are tolerable because nothing about the application punishes them. A pharmaceutical-grade active ingredient is held to a different universe of expectations. Every impurity has to be identified, quantified, and controlled; the process has to be validated so that batch after batch comes out the same; and the whole operation has to run under documented quality systems, in facilities that regulators can inspect.
Re-grading an old molecule therefore means far more than "make it cleaner." It means developing analytical methods sensitive enough to see impurities that never mattered before, characterizing where those impurities come from and proving they stay within safe limits, demonstrating stability over time, and locking down a reproducible, scalable manufacturing route. It means quality documentation, batch records, and the kind of process control that turns a chemical into a medicine. This is genuine chemistry and engineering work — and it is precisely the work that a resurging old molecule generates. The demand a repurposing story produces is a demand for GMP-grade supply that never needed to exist while the compound was only a dye.
A faster lane — because the molecule is already known
The other reason old molecules are attractive is regulatory. A brand-new chemical entity arrives with everything unknown: how it behaves in the body, what it does at the doses that matter, whether it is safe at all. A repurposed molecule arrives with a track record. Years of human exposure, published literature, and existing safety data mean a developer can often lean on what is already known rather than rebuilding the entire evidence base from zero. Qualitatively, that shortens and de-risks the path — the questions that remain tend to be about the new use and the new formulation, not about the molecule's basic safety.
None of this makes approval automatic. A new indication still has to be proven, and a new route of administration — turning a topical or oral compound into an injectable, say — raises real questions of its own. But the starting line is further along. For a manufacturer weighing where to put capacity, "known molecule, known safety, new indication" is a materially different risk profile from "everything unproven," and it is one of the reasons a resurging old compound can be a better bet than a shiny new one.
Who feels this demand first
API and CDMO manufacturers are where the re-grading demand physically lands. Someone has to build the validated, inspectable process that turns an old compound into a pharmaceutical-grade ingredient, and that someone is a contract or captive manufacturer with GMP capability. For them, an old molecule with resurging demand is a favorable order: understood chemistry, lower synthetic risk, and a customer who needs the grade more than they need novelty.
Specialty and repurposing developers are the ones who spot the new indication and carry it through the clinic. Their value is rarely the molecule itself — which anyone can make — but the method of use, the formulation, and the clinical evidence they generate around it. Generic and fine-chemical suppliers sit in a third position: they already know how to make many of these established compounds, and a resurgence turns a low-margin commodity into something worth re-tooling for. Reading which old molecule is about to move — before the order arrives — is worth more to each of these players than any amount of headline-chasing.
The caveats: not every old molecule is a comeback
The economics come with an important asymmetry. For a molecule this old, the original composition-of-matter protection — the patent on the substance itself — is almost always long gone. Value therefore doesn't come from owning the molecule; it comes from owning the method: a specific new use, a particular formulation, or a proprietary manufacturing process. A repurposing story with no defensible method or formulation position is a scientific insight, not necessarily a business. The manufacturers who win here are the ones who understand that the moat has moved from the compound to how it is used and made.
And the pattern is not a guarantee. For every Rose Bengal, there are countless old compounds that never find a second act — polypharmacology means a molecule can hit other targets, not that it usefully will. Most don't. That is exactly why demand has to be read rather than assumed: what matters is which old molecules are actually resurging, not the general hope that some might. When science quietly discovers a new mechanism or indication for a known compound, the molecule stays the same — but the demand for it, and the standard it must be made to, jump. The radar catches these because it reads demand, not headlines — and demand doesn't care how old the molecule is.
Editorial commentary from the Knitify Pharma Demand Radar. Not investment, legal, regulatory, or medical advice.